Pyxis Oncology, Inc.
PYXS
$1.14
-$0.05-4.20%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -95.23M | -77.33M | -57.36M | -59.20M | -57.80M |
| Total Depreciation and Amortization | 2.42M | 2.98M | 3.12M | 2.91M | 2.85M |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 27.97M | 28.50M | 8.07M | 10.42M | 11.59M |
| Change in Net Operating Assets | 5.35M | -11.82M | -7.47M | -10.68M | -21.22M |
| Cash from Operations | -59.50M | -57.67M | -53.64M | -56.55M | -64.58M |
| Capital Expenditure | 0.00 | -237.00K | -237.00K | -298.00K | -2.56M |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | 1.00K | 6.66M | 6.66M |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 42.47M | 8.39M | -8.04M | -8.06M | -28.06M |
| Cash from Investing | 42.47M | 8.16M | -8.27M | -1.70M | -23.95M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 9.51M | 67.22M | 67.24M | 58.11M | 64.08M |
| Repurchase of Common Stock | -7.70M | -7.89M | -292.00K | -684.00K | -641.00K |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 0.00 | 0.00 | -7.70M | 0.00 | -- |
| Cash from Financing | 1.82M | 59.33M | 59.25M | 57.43M | 63.44M |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -15.21M | 9.81M | -2.66M | -824.00K | -25.09M |